ProMark: Clinical Validation

Strong clinical validation conveys assured confidence in ProMark.

 

To-date, ProMark has been a focus of 4 multi-center clinical studies analyzing 1,200+ patient samples:

1. Lethal Outcome: Prediction of death after radical prostatectomy
2. Biopsy Simulation: Accurate risk prediction despite sampling error
3. Biopsy Clinical Test Development:  Final Marker model lock down
4. Clinical Validation: Validation of locked mode

Primary publications:

Development and Clinical Validation of an in situ Biopsy Based Multi-Marker: Assay for Risk Stratification in Prostate Cancer
Clinical Cancer Research, 2015 Mar 2. pii: clincanres.2603.2014
Learn more about these study results.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality
Proteome Science, Shipitsin et al. Proteome Science 2014, 12:40

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
British Journal of Cancer, (2014) 111, 1201–1212 | doi: 10.1038/bjc.2014.396

Economic Analysis:

Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer
The Oncologist, 10.1634/theoncologist.2015-0214.doi: 10.1634/theoncologist.2014-0167

Abstracts:

Distinguishing aggressive versus nonaggressive prostate cancer using a novel prognostic proteomics biopsy test, ProMark.
Presented as poster at 2014 ASCO Annual Meeting